Aera Therapeutics
Aera Therapeutics, headquartered in Cambridge, MA, focuses on advancing genetic medicines using a proprietary protein nanoparticle delivery platform and a therapeutic enzyme platform for gene editing.
Services
Aera Therapeutics offers advanced genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. The company focuses on the development and distribution of genetic medicines that target various therapeutic applications. This includes utilizing their technology for gene editing and other innovative genetic treatment methods.
Founders
Aera Therapeutics was launched with significant financial backing, securing $193 million to support its mission of advancing next-generation genetic medicines. The founders and key stakeholders are committed to leveraging this investment to develop and deliver transformative therapies.
Products
Aera Therapeutics develops genetic medicines using its proprietary protein nanoparticle (PNP) delivery platform. This includes a specialized therapeutic enzyme platform that is integral for gene editing. These products aim to address a wide array of therapeutic needs by leveraging human proteins for targeted genetic interventions.
Headquarters
Aera Therapeutics is headquartered at 300 Technology Square, Cambridge, MA 02139. This location situates the company in a prominent hub of biotechnology and pharmaceutical innovation, providing access to cutting-edge research and development facilities.
Sector
Aera Therapeutics operates within the biotechnology and pharmaceutical sectors, focusing specifically on genetic medicine and gene editing technologies. The company's use of proprietary platforms positions it at the forefront of genetic treatment advancements with the aim to develop and implement transformative therapies.